title: Serum N-acetyl-beta-D-glucosaminidase activity in a genetic rat model of non-insulin-dependent diabetes mellitus.
abstract: Serum N-acetyl-beta-D-glucosaminidase activity (NAG) is a possible predictor of vascular injury in hypertension. We assessed whether the activity of this enzyme reflects vascular damage in a genetic rat model of non-insulin-dependent diabetes mellitus (NIDDM) in humans. Otsuka Long-Evans Tokushima Fatty (OLETF) rats fed a regular chow were treated with the angiotensin converting enzyme (ACE) inhibitor imidapril for 16 wk. Systolic blood pressure increased in a time-dependent manner in the untreated OLETF rats as compared with that in the control Long-Evans Tokushima (LET) rats. The blood pressure elevation was associated with increases in cardiac and aortic weight. Imidapril treatment significantly attenuated the blood pressure elevation and reduced the increases in cardiac and aortic weight. The untreated OLETF rats had higher plasma glucose and insulin concentrations than did the LET rats and presented with glucosuria at the age of 22 wk. Imidapril treatment strikingly decreased plasma glucose levels and the glucosuria. Plasma insulin concentrations decreased, approaching those of the non-diabetic control LET rats. ACE inhibitor treatment attenuated the nodular lesions in the glomeruli of OLETF rats and improved the kidney function. Serum NAG activity increased significantly by 35% in the untreated rats; this increase was attenuated significantly by imidapril treatment. The reduction in serum NAG activity correlated with improvement in cardiovascular injury. In contrast, there were no changes in urinary NAG excretion in the three OLETF rat groups. In addition, NAG excretion did not correlate with indices of cardiovascular injury. These data suggest that serum NAG activity is useful in predicting injury in the cardiovascular system in rats with diabetes mellitus.
authors.affiliation: Second Department of Medicine, University of Tokyo, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Uehara
authors.forename: N
authors.initials: N
authors.lastname: Hirawa
authors.forename: Y
authors.initials: Y
authors.lastname: Kawabata
authors.forename: A
authors.initials: A
authors.lastname: Numabe
authors.forename: H
authors.initials: H
authors.lastname: Nagoshi
authors.forename: T
authors.initials: T
authors.lastname: Gomi
authors.forename: T
authors.initials: T
authors.lastname: Ikeda
authors.forename: A
authors.initials: A
authors.lastname: Goto
authors.forename: T
authors.initials: T
authors.lastname: Toyo-oka
authors.forename: M
authors.initials: M
authors.lastname: Omata
mesh_terms: D000118:Acetylglucosaminidase / Q000097:blood*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D003404:Creatinine / Q000652:urine; D003924:Diabetes Mellitus, Type 2 / Q000201:enzymology* / Q000235:genetics* / Q000473:pathology; D005947:Glucose / Q000378:metabolism; D006439:Hemodynamics / Q000502:physiology; D007093:Imidazoles / Q000494:pharmacology; D048289:Imidazolidines; D007668:Kidney / Q000473:pathology; D007677:Kidney Function Tests; D009569:Nitric Oxide / Q000652:urine; D009929:Organ Size / Q000187:drug effects; D051381:Rats; D011919:Rats, Inbred Strains
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D001786:Blood Glucose; D007093:Imidazoles; D048289:Imidazolidines; D009569:Nitric Oxide; D003404:Creatinine; C065166:imidapril; D000118:Acetylglucosaminidase; D005947:Glucose